Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose study of DNL919 in healthy participants
NL-OMON51440Phase 1Active, not recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing DNL919 with Placebo (2 arms). Primary endpoint: Incidence, severity, and seriousness of treatment-emergent adverse events. Started Jul 2022; status: active, not recruiting.
02
Drugs
DNL919
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON51440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51440.